Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 4/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9508136 | 1.00 | MME (0.59) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| SCHEMBL891432 | 1.00 | MME (0.59) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| Hydrochloric Acid SCHEMBL5691387 | 0.98 | MME (0.57) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| Valine SCHEMBL27667759 | 0.85 | SLC1A3 (0.53) | MMEMMP2MMP9L3MBTL1 | |
| SCHEMBL7379335 | 0.85 | MME (0.70) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| SCHEMBL157547 | 0.85 | MME (0.61) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| SCHEMBL9068541 | 0.85 | MME (0.70) | MMENPSR1CYP1A2NAALAD2FOLH1 | |
| SCHEMBL156975 | 0.84 | FOLH1 (0.58) | MMENAALAD2FOLH1L3MBTL1 | |
| SCHEMBL156976 | 0.84 | FOLH1 (0.58) | MMENAALAD2FOLH1L3MBTL1 | |
| SCHEMBL1803033 | 0.84 | EPHX1 (0.55) | MMECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 563 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352074-A1 | ANTIVIRAL LARAZOTIDE DERIVATIVES | Fasano, Alessio (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2022259049-A1 | ANTIVIRAL LARAZOTIDE DERIVATIVES | FASANO ALESSIO (US) | 2022-12-15 | — | — | WO | claimed |
| CN-114813557-A | Quantitative detection kit for p-hydroxyphenylalanine in urine and detection method thereof | 兰州大学第一医院 | 2022-07-29 | — | — | CN | claimed |
| CN-114716635-A | Multifunctional polyurea-amino acid derivative and preparation method and application thereof | 四川大学 | 2022-07-08 | — | — | CN | claimed |
| US-20200325190-A1 | Modification and Compositions of Human Secretoglobin Proteins | APC RESEARCH ASSETS, LLC | 2020-10-15 | — | — | US | claimed |
| CN-211627380-U | Convenient p hydroxy phenyl alanine urine detection test paper box that detects | 江苏东博生物医药有限公司 | 2020-10-02 | — | — | CN | claimed |
| CN-211426509-U | P-hydroxy phenylalanine urine detection kit with good protection performance | 江苏东博生物医药有限公司 | 2020-09-04 | — | — | CN | claimed |
| CN-211426281-U | Anti-falling p-hydroxyphenylalanine urine detection kit | 江苏东博生物医药有限公司 | 2020-09-04 | — | — | CN | claimed |
| US-20190337999-A1 | Modification and Compositions of Human Secretoglobin Proteins | APC RESEARCH ASSETS, LLC | 2019-11-07 | — | — | US | claimed |
| US-10294285-B2 | Modification and compositions of human secretoglobin proteins | CLARASSANCE, INC. | 2019-05-21 | — | — | US | claimed |
| US-6949660-B2 | Chiral (1pyrrolino) fullerene derivatives | SETH NANOTECHNOLOGY, INCORPORATED (US) | 2005-09-27 | — | — | US | claimed |
| US-6790963-B2 | STEREOSPECIFIC PHOTODYANMIC THERAPY SENSITIZERS TO ENHANCE CYTOTOXICITY OF ANTITUMOR AGENTS; FULLEROPYRROLIDINE COMPOUNDS | CHIANG, LONG Y. (TW) | 2004-09-14 | — | — | US | claimed |
| US-20040034205-A1 | Chiral (1pyrrolino) fullerene derivatives | CHIANG, LONG Y. | 2004-02-19 | — | — | US | claimed |
| US-20030013861-A1 | E-isomeric fullerene derivatives | CHIANG, LONG Y. (TW) | 2003-01-16 | — | — | US | claimed |
| US-20030009036-A1 | E-isomeric fullerene derivatives | SETHNANOTECHNOLOGY, INCORPORATED | 2003-01-09 | — | — | US | claimed |
| CN-1317484-A | Fullerene derivatives of the E-isomer | JIANG LONGYONG (CN) | 2001-10-17 | — | — | CN | claimed |
| EP-1132380-A1 | E-Isomeric fullerene derivatives | Chiang, Long Y. (TW) | 2001-09-12 | — | — | EP | claimed |
| EP-0836616-A1 | MACROLIDES | Novartis AG (CH) | 1998-04-22 | — | — | EP | claimed |
| WO-1997002285-A1 | MACROLIDES | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | claimed |
| US-4145255-A | ENZYMATIC OXIDATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 1979-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013861-A1 | E-isomeric fullerene derivatives | PCBP1, EFNA1, DPYD | MME 3759/4885NPSR1 1480/4885CYP1A2 50/4885 |
| US-20040034205-A1 | Chiral (1pyrrolino) fullerene derivatives | PCBP1, RPLP1, RPLP2 | MME 4813/4885NPSR1 1515/4885CYP1A2 86/4885 |
| US-20030009036-A1 | E-isomeric fullerene derivatives | PCBP1, EFNA1, DPYD | MME 3759/4885NPSR1 1480/4885CYP1A2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.